HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Master Thesis

Devenir réfractif des enfants traités par injection intra-vitréenne de bevacizumab ou par laser pour une rétinopathie du prématuré

Abstract : Purpose: to compare the refractive outcomes of intravitreal bevacizumab (IVB) with peripheral retinal photocoagulation (PRP) in infants treated for posterior type 1 ROP. Methods: a retrospective study was conducted in Bordeaux, France, during 2010 to 2020. 30 preterm infants with ROP requiring treatment were included. The main outcome was spherical equivalent (SE) in diopters, determined by cycloplegic refraction at 9 months corrected age. Infants treated with IVB + PRP were also included in the IVB group. Side effects of the treatment have also been studied. Results: the final analysis included 24 eyes in the PRP group and 22 eyes in the IVB group. There was no statistically significant difference in mean SE between the IVB and PRP group. Mean SE was -1.8 +/- 4.45 in the PRP group and -0.14 +/- 3.3 in the IVB group (P=0.2137). Mean spherical power was -1.14 +/- 4.05 in the PRP group and +0.57 +/- 3.2 in the IVB group (P=0.1463). Very high myopia (>-6 D) occurred in 1 of 22 (4.55 %) eyes that received intravitreal bevacizumab and in 6 of 24 (25 %) eyes that received laser treatment (P=0.0984). No systemic or local toxic effects attributable to the administration of bevacizumab were observed. Conclusion :in our study, preterm infants treated with IVB were no significantly less myopic than those treated with PRP at 9 months corrected age. Despite, our results suggest that IVB has better refractive outcomes than PRP treatment and add to existing evidence on the advantages of primary IVB treatment. It is necessary to confirm this trend in a large and long-term study, especially with the visual acuity.
Complete list of metadata

Contributor : Médecine Ub Connect in order to contact the contributor
Submitted on : Tuesday, July 6, 2021 - 11:33:59 AM
Last modification on : Friday, July 9, 2021 - 3:48:02 AM
Long-term archiving on: : Thursday, October 7, 2021 - 6:28:22 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-06-25

Please log in to resquest access to the document


  • HAL Id : dumas-03279104, version 1



Diane Levesque. Devenir réfractif des enfants traités par injection intra-vitréenne de bevacizumab ou par laser pour une rétinopathie du prématuré. Sciences du Vivant [q-bio]. 2021. ⟨dumas-03279104⟩



Record views